Novartis China

Novartis is committed to researching, developing, and producing high-quality innovative medicines. Novartis' product portfolio covers multiple disease areas, including hypertension, cardiovascular, metabolic, ophthalmology, central nervous system, respiratory, hepatology, immunology, and dermatology. Novartis is dedicated to reimagining medicine to improve people's quality of life and extend human lifespan. As a globally leading pharmaceutical company, we leverage innovative science and digital technologies to create transformative treatments in areas with significant healthcare needs. In the exploration of new drugs, we persistently innovate, with our R&D investment consistently ranking among the top in the global industry. Nearly 800 million patients worldwide have benefited from Novartis products. Meanwhile, we continuously explore more innovative ways to make our breakthrough therapies accessible to more patients. Novartis has approximately 110,000 employees from over 140 countries around the world. The Chinese name of Novartis, "诺华," signifies "a promise to China," fully reflecting our long-term commitment to China and its people. As early as 1886, one of Novartis' predecessors, Geigy, had already promoted its dye business in China. In 1979, just one year after China announced its reform and opening-up policy, another predecessor of Novartis, Ciba-Geigy, established a representative office in Beijing.